The Effects of TMZ on Diabetic Nephropathy

Status Not yet recruiting

Clinical Trial Summary

With the improvement of people's living standard, the prevalence of Diabetes is increasing year by year. In present, 350 million people worldwide are suffering from diabetes, and by 2035, there will be as high as 600 million. Diabetes causes a variety of complications, including diabetic nephropathy, which is one of the most common complications of Diabetes. Diabetic nephropathy is a microvascular complication of diabetes. Microalbuminuria and glomerular filtration rate decrease are the main manifestation. Even more, it can progress to end-stage renal changes. Data showed that diabetic nephropathy accounts for about 40% of patients with end-stage renal disease receiving renal replacement therapy. However, the treatment of diabetic nephropathy is still lacking. In the past 40 years, few drugs have been proven to ameliorate the progression of diabetic nephropathy. Even though, the renal function of a large number of diabetic nephropathy patients is gradually deteriorating. Therefore, it is urgent to find a therapeutic drug that acts on different targets. Trimetazidine is a piperazine derivative. It is mainly used in the treatment of stable angina pectoris. Its safety has been well verified. In recent years, the role of trimetazidine in acute renal damage has been widely reported. A large number of studies have shown that trimetazidine can reduce the effect of contrast agent on renal function and reduce the incidence of contrast nephropathy. There fore, Trimetazidine is a promising drug for delaying the progression of diabetic nephropathy.

Clinical Trial Description

In the present study, there will be 2 groups last for 6 months. One is the control group, who will not receive trimetazidine and the another is the trimetazidine group, who will receive the treatment of trimetazidine, 35mg bid orally. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05147194
Study type	Interventional
Source	Tongji Hospital
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	January 1, 2022
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Terminated	`NCT01575379` - A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes	Phase 4
Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Not yet recruiting	`NCT04084886` - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Active, not recruiting	`NCT04869761` - Stem Cell Therapy for Chronic Kidney Disease	Phase 1
Recruiting	`NCT04570735` - MRI Biomarkers in Diabetic Kidney Disease
Completed	`NCT03165240` - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated	Phase 1
Completed	`NCT01968668` - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)	Phase 2
Completed	`NCT02552277` - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy	Phase 2
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Terminated	`NCT02410005` - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)	Phase 2/Phase 3
Unknown status	`NCT01918488` - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease	N/A
Completed	`NCT00915200` - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy	Phase 2
Completed	`NCT03165227` - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)	Phase 1
Active, not recruiting	`NCT04531163` - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy	Phase 2/Phase 3
Active, not recruiting	`NCT03620773` - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes	Phase 1/Phase 2
Completed	`NCT03618420` - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function	Phase 1/Phase 2
Not yet recruiting	`NCT03284996` - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.	N/A
Completed	`NCT03334318` - PERL Continuous Glucose Monitoring (CGM) Study
Completed	`NCT04380584` - Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.